GlassScriptPhysician profile
Vinayak Kottoor
NPI 1689687287
$708.92
in general payments reported to CMS, 2019-2025
14 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6.40 · 2021: $50.56 · 2022: $59.11 · 2023: $202 · 2024: $270 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $192.52 | 2023-2025 | Jardiance, Zepbound |
| Novo Nordisk INC | $118.32 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $95.86 | 2022-2024 | |
| Pfizer INC. | $72.19 | 2023 | |
| Novavax INC | $36.52 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Abbott Laboratories | $36.30 | 2022-2024 | Octrode |
| Abbvie INC. | $34.98 | 2023 | |
| Merck Sharp & Dohme LLC | $24.76 | 2025 | Capvaxive, Enflonsia |
| Roche Diagnostics Corporation | $23.63 | 2021 | |
| Medtronic, INC. | $23.17 | 2025 | Intellis Adaptivestim |
| Exact Sciences Corporation | $15.19 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $14.89 | 2023 | Repatha, Otezla |
| Cranial Technologies, INC | $13.36 | 2021 | |
| Travere Therapeutics, INC. | $7.23 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinayak Kottoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.